Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And so we're excited about our ability to grow faster than the market |
| And this is a key part of our path to getting to cash flow positive, as you had alluded to, Kyle, improving gross margins and also being very disciplined with respect to our OpEx |
| We think that the opportunity is very strong |
| The -- on top of our long-term revenue target of reaching at least $500 million in 2026, we have several gross margin initiatives that are expected to lower production costs, better utilized manufacturing overhead and improve our supply chain efficiency |
| Our team executed aggressive goals to ramp Revio manufacturing and scale the installed base, which enabled PacBio to grow revenue 56% in 2023 to $200.5 million, which was ahead of our expectations |
| But what I do know is the number of samples coming on to this system is accelerating, and it's more than ever in the history of the company, and I think that's at a fundamental level, that bodes well for driving revenue growth, driving adoption, driving gross margin expansion and then driving really ubiquity in the market, which is really our core objective in this phase of our strategic plan, right, driving adoption, building the confidence in the data type and demonstrating why HiFi is really the way to go with respect to Germline Genomics |
| We're going to start to see some of these cost reductions as early as Q2, and then we'll continue to improve even in the subsequent quarters such that the second half, our gross margins continue to improve relative to the first half |
| Additionally, compared to the 2023 non-GAAP gross margin, we expect improvement driven by a mix shift toward higher-margin consumables and higher consumable manufacturing volumes as well as instant manufacturing optimization, helping to drive lower manufacturing unit costs |
| We believe this momentum sets us up for another year of growth as we continue to see growing interest in HiFi for larger-scale human genomics and see it becoming more mainstream in genomic testing |
| So for example, one of our customers is using it for wastewater testing, which makes total sense because that's where the earlier you detect a variant that identifies a pathogen, the soon -- that obviously has benefits for the community |
| We certainly have a pipeline that is encouraging for us, which is how we came up with the range |
| And of course, improving manufacturing yields and value engineering to drive down the bill of materials further for especially on the insurance side, but also on the consumables side |
| These programs, along with the product mix shift towards consumables are expected to improve our gross margins |
| As a result, customers are getting a better user experience |
| The region's record quarter was driven by continued growth in instruments and consumables from both new and existing customers |
| And so you saw we just recently launched some new kits, and those kits are additive to the consumable revenue line, and we've seen strong uptake on particularly the Connect’s kit, which we've talked about, over 115 customers have ordered from us at this point |
| That new leasing partner gives us the ability to do more creative financing arrangements where the leasing partner takes some of the financial exposure, but we obviously get the benefit to our customers, and we still get healthy revenue from that |
| We've been extremely pleased with our customer enthusiasm and uptake for these kits, and we now have orders from over 115 different customers |
| And I think that's really, really exciting |
| Our HiFi Prep Kit and HiFi Plex Prep Kit 96 offers customers the potential for up to a 60% decrease in workflow time and up to a 40% reduction in costs and further lowers the DNA input requirements |
| What's implied in our guidance is that our gross margins will improve this year |
| We've been especially pleased with the number of new customers adopting Revio, as nearly 30% of Revio systems ordered in the fourth quarter were from new PacBio customers and almost 40% of Revio systems ordered in 2023 were from new PacBio customers |
| I feel like our quality is still the best in the market |
| Finally, to wrap it up, last week was the annual Advances in Genome Biology and Technology Conference, or AGBT, and it was encouraging to see the impact that HiFi long-read sequencing had on the research community and the desire for researchers to look deeper and assemble more information from the genome than ever before |
| And so that's another positive factor that drives consumables up |
| We're also making solid progress on converting existing PacBio customers over to Revio, as about one-third of our Sequel II and IIe customers have now ordered Revio |
| And we expect to have a good year in Europe and continue growing, but there is that friction in the system |
| So, first with gross margins, I do expect over the course of the year, we are going to see gross margins improving and therefore, you get into exit rates |
| And it's super exciting because every time we go to one of these conferences, more samples get added to the funnel and significantly more samples |
| Moving down the P&L, we expect the 2024 non-GAAP gross margin to be in the range of 36% to 39%, and -- we do believe that gross margins will improve over the course of the year |
| Statement |
|---|
| Gross profit in the fourth quarter of 2023 and fourth quarter of 2022 included inventory reserves and loss on purchase commitments totaling approximately $9.3 million and $7.1 million, respectively, primarily due to the continued decline in Sequel II/IIe consumable demand in the transition to the Revio platform as well as the decline in Sequel II instrument demand from predominantly one customer in China |
| So even with consumables being higher, we did have some yield challenges in the fourth quarter, nothing that significant, but probably had some impact there |
| And as a result, in our guidance, we significantly took down our forecast for China for the year |
| But in the fourth quarter, we have had some yield challenges on the consumables, which have impacted us a little bit, that wouldn't be factored into your calculation |
| As a reminder, inventory reserve charges associated with the decline in SQL 2 2E demand in place of higher Revio demand represented a headwind of approximately 700 basis points in 2023 |
| So I know you said your sales cycles are extended with general weakness in the funding environment |
| But what we see in China is we do see funding challenges in China that are making it difficult for the smaller labs to drive into Revio |
| Based off what we've seen quarter-to-date, we expect the first quarter revenue to be lower compared to the fourth quarter of 2023 with Revio system shipments flat to slightly down sequentially with lower ASPs and total consumable revenue approximately flat |
| It's actually one of the biggest areas of challenge for us as we look into 2024 |
| We talked about China a lot already today, and we've emphasized that, but also even in Europe, interest rates and the funding environment still continue to be challenged |
| Of course, China is challenged |
| It has gotten a little bit worse, I would say |
| Additionally, persistent inflation and high interest rates are lengthening sales cycles globally |
| And so I'm sure that creates some friction in the sales selling process |
| But of course, there could be risks that are out there, perhaps outside of your control that make it so you end up towards the lower end of the range |
| Now things get a lot worse |
| So I wanted to ask, at AGBT, you talked about some of this cautious capital spending that you're seeing at customers |
| And I was told we had 2.3 million social impressions and the next highest person was like almost 10 times lower than where we were |
| For example, the funding environment in China is impacting our ability to further expand our Revio installed base in the country, specifically with smaller volume academic labs |
| And effectively, what the Street would see is lower instrument ASP maybe a little bit |
Please consider a small donation if you think this website provides you with relevant information